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Burkholderia pseudomallei and Burkholderia mallei, the etiologic agents of melioidosis and
glanders, respectively, cause severe disease in humans and animals and are considered
potential agents of biological warfare and terrorism. Diagnosis and treatment of infections
caused by these pathogens can be challenging and, in the absence of chemotherapeutic
intervention, acute disease is frequently fatal. At present, there are no human or veterinary
vaccines available for immunization against these emerging/re-emerging infectious
diseases. One of the long term objectives of our research, therefore, is to identify and
characterize protective antigens expressed by B. pseudomallei and B. mallei and use
them to develop efficacious vaccine candidates. Previous studies have demonstrated
that the 6-deoxy-heptan capsular polysaccharide (CPS) expressed by these bacterial
pathogens is both a virulence determinant and a protective antigen. Consequently, this
carbohydrate moiety has become an important component of the various subunit vaccines
that we are currently developing in our laboratory. In the present study, we describe
a reliable method for isolating CPS antigens from O-polysaccharide (OPS) deficient
strains of B. pseudomallei; including a derivative of the select agent excluded strain
Bp82. Utilizing these purified CPS samples, we also describe a simple procedure for
covalently linking these T-cell independent antigens to carrier proteins. In addition, we
demonstrate that high titer IgG responses can be raised against the CPS component of
such constructs. Collectively, these approaches provide a tangible starting point for the
development of novel CPS-based glycoconjugates for immunization against melioidosis
and glanders.
Keywords: Burkholderia pseudomallei , Burkholderia mallei , capsular polysaccharide, glycoconjugate, vaccine,
immunization
INTRODUCTION
Burkholderia pseudomallei and Burkholderia mallei, the causative
agents of melioidosis and glanders, respectively, are both CDC
category B select agents (Howe and Miller, 1947; Redfearn et al.,
1966; Yabuuchi et al., 1992). These facultative intracellular, Gram-
negative pathogens are highly infectious via the respiratory route,
and can cause severe, debilitating and often fatal diseases in
humans and animals (Wiersinga et al., 2006; Whitlock et al., 2007;
Galyov et al., 2010; Limmathurotsakul et al., 2012). The clinical
symptoms of melioidosis and glanders tend to be multi-faceted
and disease may manifest as chronic or acute localized infec-
tions, acute pulmonary infections, or fulminating septicemias.
Treatment of these diseases can be challenging and even with
appropriate chemotherapeutic intervention, mortality rates are
unacceptably high (White, 2003; Khan et al., 2012; Meumann
et al., 2012). At present, there are no human or veterinary
vaccines available for immunization against melioidosis or glan-
ders (Bondi and Goldberg, 2008; Sarkar-Tyson and Titball, 2010;
Peacock et al., 2012).
Due to the potential misuse of B. pseudomallei and B. mallei
as agents of biological warfare and terrorism, as well as their
impact on public health in endemic regions, there has been a
resurgence of interest in developing effective melioidosis and
glanders vaccines (Rotz et al., 2002; Voskuhl et al., 2003; Peacock
et al., 2012). To date, however, attempts to identify suitable candi-
dates have been met with limited success. Recent studies indicate
that vaccination of mice with lipopolysaccharide (LPS), cap-
sular polysaccharide (CPS), non-viable (heat-killed/irradiated),
or live-attenuated preparations of B. pseudomallei or B. mallei
provide varying degrees of protection against a lethal challenge
(Atkins et al., 2002; Nelson et al., 2004; Stevens et al., 2004;
Ulrich et al., 2005; Whitlock et al., 2008; Sarkar-Tyson et al., 2009;
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Norris et al., 2011). Interestingly, whole cell preparations that fail
to protect mice against challenge all appear to stimulate either
mixed T-helper 1 (Th1)/T-helper 2 (Th2)-like or Th2-like biased
cellular and humoral responses (Amemiya et al., 2002; Ulrich
et al., 2005; Amemiya et al., 2006). In contrast, preparations
affording protection appear to stimulate Th1-like biased cytokine
(IL-2 and IFN-γ) and immunoglobulin responses (IgG2a>IgG1)
(Ulrich et al., 2005; Amemiya et al., 2006). Based upon these
findings, immunity to melioidosis and glanders appears to be
complex, requiring both humoral and cell-mediated responses.
In addition, these studies suggest that whole cell or subunit based
vaccine candidates promoting Th1-like responses will likely be
required to immunize against disease caused by B. pseudomallei
and B. mallei.
Capsular polysaccharides are a major component of Gram-
negative cell envelopes. Structurally diverse in nature, these highly
hydrated antigens exhibit a variety of important biological func-
tions including resistance to desiccation, adherence to host tissues
and protection against innate/acquired immune defenses (Bazaka
et al., 2011). Curiously, B. pseudomallei and B. mallei isolates
appear to be capable of expressing only a limited repertoire
of structurally diverse CPS antigens. In fact, it has even been
suggested that virulent clinical and/or environmental isolates of
these pathogens can be defined by a single CPS serotype (Zou
et al., 2008; Sim et al., 2010). At present, the significance of
these observations with regard to virulence and evasion of host
immune responses remains to be fully determined. Nevertheless,
this attribute certainly bodes well from a vaccine development
standpoint.
Previous studies have demonstrated that the predominant
CPS antigen expressed by B. pseudomallei is an unbranched
homopolymer consisting of monosaccharide repeats having the
structure -3)-2-O-acetyl-6-deoxy-β-D-manno-heptopyranose-
(1- (6-deoxy-heptan; Perry et al., 1995). Although it has been
recently shown that B. mallei also expresses an identical CPS
antigen, studies indicate that for the most part, isolates of
the closely related but non-pathogenic species, Burkholderia
thailandensis, do not (Brett et al., 1998; DeShazer et al., 2001;
Reckseidler et al., 2001). Based upon these observations, it has
been proposed that the relative avirulence of B. thailandensis,
in comparison to B. pseudomallei and B. mallei, may be due in
part to the absence of this carbohydrate antigen (DeShazer et al.,
2001; Reckseidler et al., 2001; Galyov et al., 2010).
Virulent isolates of B. pseudomallei and B. mallei, whether
of human or veterinary origin, all appear to express the
6-deoxy-heptan CPS antigen (Zou et al., 2008). Importantly,
previous studies by Reckseidler et al. (2001) have demon-
strated that CPS-deficient mutants of B. pseudomallei are avir-
ulent in a hamster model of infection. Similarly, studies by
DeShazer et al. (2001) have also demonstrated that CPS-
deficient mutants of B. mallei are avirulent in both murine
and hamster models of infection. More recently, it has been
shown that capsule production by B. pseudomallei contributes
to resistance to phagocytosis by reducing C3b deposition on
the surface of the bacterium, again implicating CPS as impor-
tant virulence determinant (Reckseidler-Zenteno et al., 2005).
Additionally, and germane to the present study, it has been
shown that murine monoclonal antibodies (mAbs) specific
for CPS are capable of passively immunizing mice against
lethal challenges of B. pseudomallei and B. mallei (Jones et al.,
2002; Zhang et al., 2011; AuCoin et al., 2012). Such find-
ings confirm the protective capacity of this surface exposed
antigen and support the rationale for exploring the use of
CPS-based glycoconjugates as melioidosis and glanders vaccine
candidates.
In this study, we describe the use of genetic, chemical, physi-
cal, and immunological approaches to facilitate the development
and preliminary testing of B. pseudomalleiCPS-based glycoconju-
gates. It is anticipated that via the application of these approaches,
we will gain valuable insights toward the rational design of glyco-
conjugate vaccines for immunization against diseases caused by
B. pseudomallei and B. mallei.
MATERIALS ANDMETHODS
STRAINS AND GROWTH CONDITIONS
The bacterial strains used in this study are described in Table 1.
Unless otherwise stated, B. pseudomallei, B. mallei, and E. coli
were grown at 37◦C on Luria Bertani-Lennox (LBL) agar or in
LBL broth. For B. pseudomallei Bp82 and its derivatives, growth
media were supplemented with 100μg/ml adenine hydrochlo-
ride (Sigma) and 5μg/ml thiamine hydrochloride (Sigma). When
appropriate, antibiotics were added at the following concentra-
tions: 25μg/ml kanamycin (Km) or 15μg/ml polymyxin B (Pm)
for E. coli and 100μg/ml (DD503) or 500μg/ml (Bp82) Km
for B. pseudomallei. Bacterial stocks were maintained at –80◦C
as 20% glycerol suspensions. Other than B. pseudomallei Bp82
and its derivatives, all studies with B. pseudomallei and B. mallei
were conducted in a CDC select agent certified biosafety level 3
containment facility.
RECOMBINANT DNA TECHNIQUES
The plasmids and oligonucleotide primers used in this study
are described in Table 1. DNA manipulations were performed
using standard methods. Restriction enzymes and T4 DNA
Ligase (New England BioLabs) were used according to man-
ufacturer’s instructions. PCR was performed using an Expand
High Fidelity PCR System (Roche Applied Science) or GoTaq
DNA Polymerase (Promega); 1M Betaine (Sigma) was included
in all PCR reactions. PCR was performed using the follow-
ing conditions: 97◦C for 5min; 30 cycles, each consisting of
97◦C for 45 s, 55◦C for 45 s, and 72◦C for 3min; a final
extension step of 72◦C for 10min was included. PCR and
restriction digested products were purified using a QIAquick
Gel Extraction Kit (Qiagen). Plasmids were purified using a
QIAprep Spin Miniprep Kit (Qiagen). Genomic DNA was puri-
fied using a Wizard Genomic DNA Purification kit (Promega).
Chemically competent E. coli TOP10 cells were transformed as
per themanufacturer’s instructions (Invitrogen). Oligonucleotide
primers were obtained from Integrated DNA Technologies
(Coralville, IA).
MUTANT CONSTRUCTION
Gene replacement experiments with B. pseudomallei were
conducted using the sacB-based vector pMo130. To construct
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Table 1 | Strains, plasmids and primers.
Strains Relevant characteristics Source or reference
E. coli
TOP10 General cloning strain: Kms, Pms Invitrogen
S17-1 Mobilizing strain: Kms, Pms Simon et al., 1983
B. pseudomalleia
1026b Clinical isolate DeShazer et al., 1997
DD503 1026b derivative; (amrR-amrAB-oprA): Kms, Pmr Moore et al., 1999
BP2683 DD503 derivative; rmlD: Kms, Pmr Heiss et al., 2012
Bp82 1026b derivative; purM: Kmr, Pmr Propst et al., 2010
RR2683 Bp82 derivative; rmlD: Kmr, Pmr This study
B. mallei
ATCC 23344 Type strain; isolated in 1944 from a human case of glanders Yabuuchi et al., 1992
PLASMIDS
pMo130 Gene replacement vector; oriT sacB: Kmr Hamad et al., 2009
pMormlD pMo130 harboring rmlD with an internal 354-bp deletion: Kmr This study
PCR PRIMERSb
BprmlD-5FH 5′-CATGAAGCTTTTCAGGACAATCACTCCCGATCCG-3′ This study
BprmlD-5RPs 5′-TTGATCACATTCGCTGCAGCACCATC-3′ This study
BprmlD-3FPs 5′-GCGATCGATTGCTGCAGGCACGGCCCA-3′ This study
BprmlD-3RXb 5′-CATGTCTAGAGACACATTCGGCGAACAATCCATG-3′ This study
aThe majority of prototype B. pseudomallei strains are resistant to high levels of Km due to expression of the AmrAB-OprA efflux pump. For genetic manipulations
this intrinsic resistance can be overcome using high (>500μg/ml) Km concentrations.
bRestriction sites are italicized.
an in-frame deletion in the O-polysaccharide (OPS)-related
biosynthetic gene, rmlD (BPSL2683), the rmlD-5FH/rmlD-5RPs
and rmlD-3FPs/rmlD-3RXb primer pairs were used to PCR
amplify ∼600 bp DNA fragments upstream (rmlD5′) and down-
stream (rmlD3′) of the gene, respectively. The rmlD5′ PCR
product was digested with HindIII and PstI and cloned into
pMo130 digested with the same enzymes resulting in plas-
mid pMormlD5′. The rmlD3′ PCR product was then digested
with PstI and XbaI and cloned into pMormlD5′ digested
with the same enzymes. The resulting plasmid was desig-
nated pMormlD (harboring rmlD with a 354-bp deletion,
rmlD).
To construct the B. pseudomallei OPS mutant strains BP2683
and RR2683, E. coli S17-1 was used to mobilize pMormlD into
B. pseudomallei DD503 or Bp82 via conjugative mating essen-
tially as previously described (DeShazer et al., 1997; Burtnick
et al., 2011). Briefly, overnight cultures of S17-1 (pMormlD)
and DD503 or Bp82 were pelleted by centrifugation, resuspended
together in 100μl of 10mM MgSO4, spotted onto LB agar plates
and incubated for 18 h at 37◦C. To select for transconjugants,
matingmixtures were plated onto LB-Km-Pm agar and incubated
at 37◦C for 48 h. To select for sucrose resistant colonies, indi-
vidual transconjugants were inoculated into yeast-tryptone (YT)
broth, incubated at 37◦C for 4–5 h, and then plated onto YT agar
containing 15% sucrose (Hamad et al., 2009). Following incuba-
tion at 37◦C for 48 h, sucrose resistant colonies were screened for
loss of the Km resistance marker by replica plating onto LB and
LB-Km. The resolved co-integrates were screened for the presence
of the mutant allele (rmlD) by PCR.
CPS PURIFICATION
LBL broth (4 × 600ml in 2 L baffled Erlenmeyer flasks) was
inoculated with B. pseudomallei BP2683 or RR2683 and incu-
bated overnight at 37◦C with vigorous shaking. Cell pellets were
obtained by centrifugation (10min at 8000 × g) and extracted
using a modified hot aqueous-phenol procedure (Perry et al.,
1995). Following extraction, the resulting phenol and aqueous
phases were combined and dialyzed against distilled water to
remove the phenol. The dialysates were then clarified by cen-
trifugation (20min at 10,000 × g) and the supernatants con-
centrated by lyophilization. The crude CPS preparations were
solubilized at 20mg/ml in RD buffer [10mM Tris-HCl (pH 7.5),
1mM MgCl2, 1mM CaCl2, 50μg/ml RNase A and 50μg/ml
DNase I] and incubated for 3 h with gentle shaking at 37◦C.
Proteinase K was then added to a final concentration of 50μg/ml
and the samples were incubated for an additional 3 h at 60◦C
after which the enzymatic digests were clarified by centrifuga-
tion (20min at 10,000 × g). CPS was then isolated from the
supernatants as precipitated gels following successive rounds of
ultracentrifugation (3 × 2 h at 100,000 × g with the pellets being
resuspended in ultrapure water between spins). After the final
spin, the gel-like pellets were resuspended in ultrapure water and
lyophilized.
To remove the rough LPS contaminants from the CPS prepa-
rations, crude samples were solubilized at 5mg/ml in 2% acetic
acid and incubated for 2 h at 100◦C. The hydrolyzed samples
were cooled to room temperature and clarified via centrifugation
(20min at 10,000 × g) following which the supernatants were
carefully removed and lyophilized to concentrate. The lyophilized
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samples were then solubilized at 20mg/ml in 100mM phos-
phate buffered saline (pH 7.4; PBS) and clarified using 0.45μm
syringe filters. The samples were loaded onto Sephadex G-50
columns (40 × 2.6 cm) equilibrated with PBS and eluted with
the same buffer. Fractions (5ml) were collected and assayed for
carbohydrate using the phenol-sulfuric acid method (Dubois
et al., 1956). Carbohydrate positive fractions eluting near the
column void volumes (∼70ml) were pooled, extensively dia-
lyzed against distilled water and lyophilized. Protein and nucleic
acid contamination of the resulting CPS preparations were
estimated by BCA assay (Pierce) and A260/280 measurements,
respectively.
NMR SPECTROMETRY
Column purified CPS was deuterium exchanged by dissolving
in D2O followed by lyophilization. Samples were then dissolved
in D2O containing a trace amount of acetone and 1H and
13C NMR spectra were obtained using a Varian Inova-500MHz
spectrometer at 50◦C using standard pulse sequences. 1H and
13C chemical shifts were measured relative to the internal ace-
tone reference (δH = 2.218 ppm; δC = 33.0 ppm) (Wishart et al.,
1995).
GLYCOCONJUGATE SYNTHESIS
Glycoconjugates were synthesized using established methodolo-
gies (Brett and Woods, 1996; Jennings and Lugowski, 1981;
Conlan et al., 2002). Briefly, purified CPS was solubilized at
5mg/ml in PBS and added to a small amber vial. To each ml
of the solution was added 6mg (∼30mM) of sodium meta-
periodate (NaIO4; Pierce). Once the crystals had dissolved by
gentle agitation, the reaction mixture was gently stirred at room
temperature for 40min. To remove any excess oxidizing agent,
the reaction mixture was applied to a Zeba Desalt Spin Column
(Pierce) equilibrated with PBS and the eluate collected. To facili-
tate conjugation of the CPS to cationized bovine serum albumin
(cBSA; Pierce), the activated CPS was added to small amber vials.
To each ml of the CPS solutions was added either 0.5, 1, or
2ml of the carrier protein (5mg/ml in PBS). Following mixing
by gentle agitation, 10μl aliquots of a sodium cyanoborohy-
dride stock (1M NaBH3CN in 10mM NaOH) were added to
each ml of the conjugation mixtures and the reactions were gen-
tly stirred at room temperature for 4 d. Following this, 10μl
aliquots of a sodium borohydride stock (1M NaBH4 in 10mM
NaOH) were added to each ml of the conjugation mixtures
and the reactions were stirred for 40min. The conjugate reac-
tions were then brought to 5ml with ultrapure water, dialyzed
against distilled water and then lyophilized. The resulting prepa-
rations were resuspended in ultrapure water as 1mg/ml stocks
and stored at −20◦C until required for use. BCA assays were used
to quantitate the protein concentrations of the glycoconjugate
stocks.
ANTIBODY PRODUCTION
Standard immunization protocols were used at Cocalico
Biologicals, Inc. to generate mouse immune serum samples.
Briefly, 6–8 week old female BALB/c mice were immunized
subcutaneously on days 0, 14, 21, and 49 with 10μg of
the CPS2B1 glycoconjugate formulated using TiterMax as an
adjuvant. Unconjugated CPS and cBSA antigens served as con-
trols. Terminal bleeds were conducted 7 days after the last
immunization. All procedures involving the mice were performed
according to protocols approved by the Cocalico Biologicals, Inc.
Animal Care and Use Committee.
SDS-PAGE ANDWESTERN IMMUNOBLOTTING
Glycoconjugate samples were solubilized in 1X SDS-PAGE sam-
ple buffer and heated to 100◦C for 5min prior to electrophoresis
on 12% Precise gels (Pierce). Proteins were visualized via stain-
ing with Coomassie Blue R-250. Whole cell lysates were prepared
from B. pseudomallei 1026b and B. mallei ATCC 23344 essentially
as previously described (Brett et al., 2011). For immunoblot anal-
yses, treated whole cell lysates or the glycoconjugate samples were
separated on 12% Precise gels and electrophoretically transferred
to nitrocellulose membranes. The membranes were blocked with
3% skim milk in high salt Tris-buffered saline (HS-TBS; 20mM
Tris, 500mM NaCl, pH 7.5) for 60min at room temperature
and then incubated overnight at 4◦C with 1/1000 dilutions of
pooled anti-CPS2B1 immune serum or the CPS-specific mAb,
3C5 (Nuti et al., 2011). To facilitate detection, the membranes
were incubated for 1 h at room temperature with 1/5000 dilu-
tions of an anti-mouse IgG horse radish peroxidase conjugate
(SouthernBiotech). The blots were then visualized using HRP
Color Development Reagent (Bio-Rad) or Pierce ECL Western
Blotting Substrate (Pierce).
QUANTITATION OF IMMUNOGLOBULIN TITERS BY ELISA
Ninenty-six-well Maxisorp plates (Nunc) were coated overnight
at 4◦C with purified CPS (10μg/ml) solubilized in carbonate
buffer (pH 9.6). The plates were blocked at room temperature
for 30min with StartingBlock T20 (TBS) Blocking Buffer (Pierce)
and then incubated for 2 h at 37◦C with the mouse serum sam-
ples serially diluted in Tris-buffered saline + 0.05% Tween 20
(TBS-T; pH 7.5) + 10% StartingBlock T20. To facilitate detec-
tion, the plates were incubated for 1 h at 37◦C with 1/2000
dilutions of an anti-mouse IgG horse radish peroxidase conju-
gate (SouthernBiotech). The plates were then developed with
TMB substrate (KPL) and read at 620 nm. The reciprocals of
the highest dilutions exhibiting ODs of >0.150 were used to
determine the endpoint titers for the individual mice. The data
was plotted and analyzed using GraphPad Prism 5 (GraphPad
Software Inc.). Statistical differences between geometric mean
IgG titers was assessed by Mann–Whitney rank sum analysis with
the significance set at P < 0.05.
CELL CULTURE AND OPSONOPHAGOCYTOSIS ASSAYS
The murine macrophage cell line RAW 264.7 (ATCC TIB-71)
was maintained in Dulbecco’s modified Eagle’s medium supple-
mented with 10% (v/v) heat inactivated (HI) fetal bovine serum
(DMEM-10; Invitrogen) and a standard mixture of antibiotics
(100U ml−1 penicillin, 100μg ml−1 streptomycin and 250μg
ml−1 amphotericin B; Sigma) at 37◦C under an atmosphere
of 5% CO2. Opsonophagocytosis assays were based upon pre-
viously described methods (Simon et al., 2011; Tennant et al.,
2011). Briefly, RAW 264.7 cells resuspended in DMEM-10 were
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transferred into 24-well tissue culture plates at a density of
∼1 × 106 cells/well and incubated overnight. B. mallei cultures
grown to early-log phase were pelleted, resuspended at a den-
sity of ∼106 cfu/ml in DMEM or DMEM containing 0.2% cBSA
or CPS2B1 mouse immune serum (pooled and HI for 30min at
56◦C) and then incubated at 37◦C for 1 h. RAW 264.7 mono-
layers were washed twice with Hanks’ Balanced Salts Solution
(HBSS; Invitrogen) prior to the addition of the opsonized bac-
terial suspensions. The monolayers were incubated with the bac-
teria at 37◦C under an atmosphere of 5% CO2 for 1 h and then
washed twice with HBSS to remove extracellular bacteria. Infected
RAW 264.7 cells were incubated in fresh DMEM-10 containing
250μg/ml km to suppress the growth of residual extracellular
bacteria. At 3 h post-infection, monolayers were washed twice
with HBSS, lysed with 0.2% (v/v) Triton X-100 (Sigma) and
serial dilutions of the lysates were plated onto LB agar sup-
plemented with 4% glycerol and incubated at 37◦C for 48 h.
Plate counts were used to enumerate bacterial loads. The data
was plotted and analyzed using GraphPad Prism 5. Statistical
differences were assessed by t-test with the significance set at
P < 0.05.
RESULTS AND DISCUSSION
PURIFICATION AND CHARACTERIZATION OF B. pseudomallei
CPS ANTIGENS
Previous studies by Perry et al. (1995) have shown that a modi-
fied enzyme hot aqueous-phenol procedure can be used to isolate
OPS and CPS antigens from wild type strains of B. pseudoma-
llei. Since both of these high molecular weight species partition
into the phenol phase during the extraction step, separation of
these antigens from one another during downstream purification
can be challenging. Fortunately, studies have demonstrated that
highly purified preparations of CPS can be obtained from natu-
rally occurring isolates of B. pseudomallei expressing rough LPS
antigens (Perry et al., 1995). Based upon these observations, we
used allelic exchange mutagenesis to construct the OPS-deficient
mutant, B. pseudomallei BP2683, to help facilitate the devel-
opment of our CPS-based glycoconjugates (Heiss et al., 2012).
Utilizing this strain, we found that we could obtain highly purified
preparations of CPS from B. pseudomallei since lower molec-
ular weight contaminants (e.g., rough LPS) rather than higher
molecular weight contaminants (e.g., smooth LPS) could be easily
separated from the homopolymer by size exclusion chromatogra-
phy (Figure 1). Recently, we have also been successful in isolating
CPS from B. pseudomallei RR2683, an OPS-deficient derivative
of the select agent excluded strain Bp82 (Propst et al., 2010).
By using this mutant strain, we now have the ability to more
safely and cost-effectively purify CPS from B. pseudomallei with-
out the requirement for BSL-3 containment which should help to
accelerate the pace of our research.
Using the purification strategy outlined in the “Materials
and Methods” section, we routinely obtain 10–15mg of CPS
per liter of BP2683 or RR2683 culture with the resulting anti-
gen preparations being devoid of any detectable protein or
nucleic acid contamination as determined by BCA assay or
UV spectroscopy. To assess the structural integrity and homo-
geneity of the CPS preparations, samples are also analyzed by
FIGURE 1 | Elution profile of column purified B. pseudomallei CPS.
Acid hydrolyzed BP2683 CPS was loaded onto a Sephadex G-50 column
and eluted with PBS. Carbohydrate positive fractions eluting near the
column void volumes (Vo) were collected and pooled for further use.
NMR spectrometry. Using this approach, 1H and 13C NMR
analyses confirm that the main component of these prepara-
tions is the desired 2-O-acetylated 6-deoxy-heptan homopoly-
mer (Figures 2A,B). In addition, such analyses indicate that the
preparations are ∼95% pure with the remainder of the sam-
ples consisting of the unique mannan CPS recently discovered by
Heiss et al. (2012).
CONJUGATION OF CPS TO CARRIER PROTEINS
To facilitate the coupling of B. pseudomallei CPS to protein car-
riers, we have found that NaIO4 is well suited for chemically
activating the polysaccharide. The decision to use NaIO4 was
based upon several considerations including (1) the absence of
amines or carboxylates in the antigen that would favor conju-
gation via other methods, (2) the relative safety of the com-
pound over alternatives such as cyanogen bromide, (3) the use
of reaction conditions to minimize the risk of reducing alkali-
sensitive O-acetyl modifications, (4) the desire to construct
neoglycoconjugates rather than cross-linked network conjugates
(Jones, 2005). Using the approach outlined in Figure 3, reactive
aldehydes incorporated into the reducing/non-reducing termini
of B. pseudomallei CPS facilitate the conjugation of the anti-
gen to carrier proteins via reductive amination. To reduce the
Schiff bases formed during the coupling reactions, NaBH3CN
was chosen as the primary reducing reagent because, unlike
NaBH4, it rapidly modifies Schiff bases but not aldehydes. Once
the CPS moieties are coupled to carrier proteins, NaBH4 is
then added to quench any residual aldehydes in the reaction
mixtures.
The CPS-based glycoconjugates synthesized in this study were
constructed using cBSA as the protein carrier. The decision to
use cBSA for this purpose was based on several considerations,
including the fact that it is (1) a well characterized immuno-
gen, (2) commercially available, and (3) affordable. To facilitate
our studies, glycoconjugates were synthesized by reacting various
ratios of chemically activated CPS and cBSA with one another
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FIGURE 2 | Structural analysis of B. pseudomallei CPS. (A) 1H NMR
and (B) 13C NMR spectra were obtained for column purified BP2683
CPS using a Varian Inova-500 MHz spectrometer. For reference purposes,
the chemical structure of the monosaccharide making up the CPS
homopolymer is inset in panel A. dH, 6-deoxy-heptose; M, mannose;
OAc, O-acetyl.
(e.g., 2:1, 1:1, and 1:2 ratios of CPS:cBSA). Following conjugation
of the antigens, the samples were examined by SDS-PAGE. Results
of these analyses indicated that in all instances, the CPS had cova-
lently linked to the protein carrier as demonstrated by the shift in
molecular weight of the cBSA relative to the unconjugated control
(Figure 4A). In addition,Western immunobloting confirmed that
the structural integrity/antigenicity of the CPSmoieties remained
intact following chemical activation and linkage to the protein
carrier based upon their reactivity with the 3C5mAb (Figure 4B).
Furthermore, studies demonstrated that by varying initial car-
bohydrate to protein ratios, we could influence the molecular
weights of the resulting glycoconjugates.
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FIGURE 3 | Generalized scheme for the conjugation of activated B. pseudomallei CPS to carrier proteins.
FIGURE 4 | Physical analysis of B. pseudomallei CPS-cBSA
glycoconjugates. (A) SDS-PAGE and Coomassie Blue staining was used to
confirm the covalent linkage of BP2683 CPS to cBSA. The positions of
protein molecular size standards are indicated on the left. (B) Western
immunobloting was also used to assess the antigenicity of the chemically
activated/coupled BP2683 CPS. The CPS + cBSA lane represents
unconjugated controls. CPS was detected using the 3C5 mAb. Lanes were
loaded with similar amounts of protein or carbohydrate to facilitate direct
comparisons.
IMMUNE RESPONSES AGAINST CPS-BASED GLYCOCONJUGATES
Efforts to overcome the poor immunogenicity of many polysac-
charides has led to the development of conjugate vaccines
(Lockhart, 2003). Covalent linkage of polysaccharides to carrier
proteins enables them to stimulate humoral immune responses
characteristic of T cell-dependent antigens. By recruiting Th cell
involvement, immunological memory is evoked, isotype switch-
ing occurs and complement-activating/opsonizing antibody iso-
types are generated. The avidities of the antibodies elicited by
glycoconjugates are also much higher than those produced by
polysaccharides alone (Kuberan and Linhardt, 2000; Lesinski and
Westerink, 2001; Weintraub, 2003).
To examine the immunogenic potential of the glycoconju-
gates synthesized in this study, mice were immunized with the
CPS2B1 construct (37% protein on a w/w basis) as well as
unconjugated controls. Analysis of the resulting serum sam-
ples indicated that mice immunized with the glycoconjugate
exhibited significantly higher anti-CPS IgG titers (45-fold) than
FIGURE 5 | Characterization of murine immune responses against the
CPS2B1 conjugate. (A) ELISA was used to determine the total serum IgG
response of mice immunized with CPS2B1 or the unconjugated controls.
Individual symbols represent a single mouse while black bars indicate
geometric means. ∗ , P < 0.05. (B) Western immunoblotting was used to
assess the reactivity of pooled anti-CPS2B1 immune serum (n = 6) with
B. pseudomallei 1026b (Bp) and B. mallei ATCC 23344 (Bm) whole cell
lysates. The positions of protein molecular size standards are indicated on
the left.
those immunized with the unconjugated control (Figure 5A). To
further examine the immune response raised against CPS2B1,
mouse serum samples were pooled and reacted against proteinase
K treated whole cell lysates of B. pseudomallei and B. mallei by
Western immunoblotting. As anticipated, results demonstrated
that the antiserum reacted strongly with CPS antigens expressed
by both pathogens (Figure 5B). In addition, the CPS2B1 anti-
serum was examined for its ability to mediate opsonophagocytic
uptake. As shown in Figure 6, pre-incubation of B. mallei with
pooled anti-CPS2B1 serum, but not pooled anti-cBSA serum,
significantly enhanced bacterial uptake into RAW 264.7 murine
macrophages.
CONCLUSIONS
Melioidosis and glanders are emerging/re-emerging infectious
diseases for which no licensed vaccines currently exist. Several
recent reports have demonstrated that mAbs specific for the
6-deoxy-heptan CPS expressed by B. pseudomallei and B. mallei
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FIGURE 6 | Opsonophagocytic uptake of B. mallei by RAW 264.7
murine macrophages. Bacterial uptake in the presence of DMEM
alone (no serum), pooled HI anti-cBSA immune serum (cBSA; n = 6) or
pooled HI anti-CPS2B1 immune serum (CPS2B1; n = 6) was
quantitated at 3 h post-infection. Values represent the means ± SD of
three independent experiments. ∗, P < 0.05.
are passively protective in animal models of infection (Jones et al.,
2002; Nelson et al., 2004; Zhang et al., 2011; AuCoin et al., 2012).
Because of this, research in our lab is focused on developing CPS-
based vaccines to immunize humans and animals against diseases
caused by these bacterial pathogens. In the present study, we have
detailed for the first time, methodologies to facilitate the isolation
and structural validation of highly purified preparations of CPS
from various B. pseudomallei 1026b derivatives. In addition, we
have described a simple strategy for covalently linking these car-
bohydrate antigens to carrier proteins. Using these approaches,
we have also demonstrated that high titer IgG responses can
be raised against the carbohydrate component of the CPS-based
glycoconjugates. Based upon these observations, studies are cur-
rently underway to assess the protective capacity of our prototype
glycoconjugates in animal models of infection.
Because of obvious limitations regarding the use of cBSA as a
carrier for vaccine development, studies are ongoing to explore
the use of licensed carriers (e.g., CRM197, CtxB, ExoA etc.) or
specific Burkholderia proteins (e.g., LolC, Hcp1, BipD etc.) for
this purpose. When doing so, it will be important to evaluate
if coupling of the CPS to the different carrier proteins affects
their stability and immunogenicity.We anticipate that approaches
such as ELISA, circular dichroism spectroscopy and protein NMR
spectrometry will be required to assess these types of issues.
Additionally, studies are being planned to investigate how dif-
fering adjuvants and dosing regimens might influence immune
responses raised against our glycoconjugates. Collectively, it is
anticipated that such studies will further provide important
insights toward the rational design of efficacious melioidosis and
glanders vaccine candidates.
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